DDInter1088 DDInter927
Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxylate] and [haloperidol]. Due to pharmacological properties, loperamide has been misused and abused to self-manage opioid withdrawal symptoms and to induce euphoria.[A251610, A251625] However, loperamide is associated with a risk for experiencing a range of adverse effects, often life-threatening, if taking for non-therapeutic reasons or at doses higher than the recommended dose.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Loperamide {u} (Compound) resembles {v} (Compound) Methadyl Acetate
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dextropropoxyphene
Loperamide {u} (Compound) resembles {v} (Compound) Clofedanol
Loperamide {u} (Compound) binds {v} (Gene) CYP3A4
Loperamide {u} (Compound) upregulates {v} (Gene) SQLE
Loperamide {u} (Compound) is included by {v} (Pharmacologic Class) Opioid Agonists
Loperamide {u} (Compound) downregulates {v} (Gene) MRPL12
Loperamide {u} (Compound) causes {v} (Side Effect) Nausea
Loperamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cholestyramine
Loperamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Loperamide (Compound) resembles Methadyl Acetate (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene
Loperamide (Compound) resembles Clofedanol (Compound)
Loperamide (Compound) binds CYP3A4 (Gene)
Loperamide (Compound) upregulates SQLE (Gene)
Loperamide (Compound) is included by Opioid Agonists (Pharmacologic Class)
Loperamide (Compound) downregulates MRPL12 (Gene)
Loperamide (Compound) causes Nausea (Side Effect)
Loperamide may cause a minor interaction that can limit clinical effects when taken with Cholestyramine
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor